CSL Limited (ASX:CSL) is a biotechnology firm that develops and delivers biotherapies and influenza vaccinations to people suffering from catastrophic diseases and chronic medical problems. CSL (ASX:CSL) offers a portfolio of life-saving medicines, including those for hemophilia. CSL Behring and Seqirus are among its parts. CSL Behring is involved in manufacturing, marketing and developing plasma therapies. It also conducts early-stage research on plasma and non-plasma therapies (excluding influenza), receives intellectual property license and royalty income. Seqirus develops influenza-related medicines and manufactures and distributes non-plasma biotherapeutic treatments. CSL reported a net profit after tax of US$2.255 billion for the fiscal year ended 30 June 2022, a 6% decrease at constant currency (CC) and at the upper end of guidance, with sales increasing 3% at CC. CSL (ASX:CSL) stated in its annual report that it remained resilient to the external environment during the fiscal year 2021/22. The company's 2030 strategy and principles continue to guide its management and frontline employees alike. According to CSL, the company’s continuous and measured investment in the business has been a key enabler of success and the company will follow this strategy in future too. CSL said that its global capital investment program has progressed as planned, making excellent strides in its research and development (R&D) pipeline.